Cargando…

Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls

BACKGROUND: Falling increases the risk for fracture. The impact of adjuvant aromatase inhibitors (AI) on the risk of falls is undefined. METHODS: A retrospective case control study was performed examining women with early stage breast cancer on adjuvant AI and matched controls without cancer. Fall a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choksi, Palak, Williams, Margaret E, Kidwel, Kelley M, Stella, Julia, Soyster, Mary, Hanauer, David, Van Poznak, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036389/ https://www.ncbi.nlm.nih.gov/pubmed/27689141 http://dx.doi.org/10.4172/2469-6684.100023

Ejemplares similares

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
por: Van Poznak, Catherine
Publicado: (2010)

Safety of aromatase inhibitors in the adjuvant setting
por: Perez, Edith A.
Publicado: (2007)

Safety of aromatase inhibitors in the adjuvant setting
por: Perez, Edith A.
Publicado: (2007)

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)

Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo, Qin-Guo, et al.
Publicado: (2016)

Weight loss and bone mineral density in obese adults: a longitudinal analysis of the influence of very low energy diets
por: Choksi, Palak, et al.
Publicado: (2018)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Precautions for Patients Taking Aromatase Inhibitors
por: Heery, Mary, et al.
Publicado: (2020)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitors in male sex
por: Singh, Santosh Kumar
Publicado: (2013)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Molecular Docking of Aromatase Inhibitors
por: Suvannang, Naravut, et al.
Publicado: (2011)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Aromatase inhibitors in stimulated IVF cycles
por: Papanikolaou, Evangelos G, et al.
Publicado: (2011)

Aromatase inhibitors in post-menopausal endometriosis
por: Polyzos, Nikolaos P, et al.
Publicado: (2011)

Management of aromatase inhibitor–induced arthralgia
por: Younus, J., et al.
Publicado: (2010)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Use of aromatase inhibitors in practice of gynecology
por: Usluogullari, Betul, et al.
Publicado: (2015)

The Role of Aromatase Inhibitors in Male Prolactinoma
por: Akirov, Amit, et al.
Publicado: (2023)

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2018)

Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review
por: Buch, Kristian, et al.
Publicado: (2018)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015)

Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
por: Hayashi, Takanori, et al.
Publicado: (2018)

Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients
por: Bell, Sarah G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h4acfr4ehvvcfomj0l0cjp4o53